CD274 and neoplasm: Specifically, treatment with the allosteric AKT inhibitor MK-2206 has previously demonstrated the capacity to downregulate PD-L1 at the transcriptional level in TNBC cell lines as well as augment the effect of a tumor specific vaccine in murine models (12, 13).